Monday, May 27, 2013
Europe's economic crisis has
created a new reality. Austerity measures at the national level have placed an
even higher premium than in the past on controlling healthcare costs, resulting
in an increasingly tough reimbursement environment and a contraction of the
European pharmaceutical market.
BioCentury's 11th annual
European Iceberg survey shows investors are clearly adapting, but they say some
young companies are still resisting reality.